Annals of Surgical Oncology

, Volume 23, Issue 2, pp 678–685 | Cite as

The Prognostic Significance of Histone Lysine Demethylase JMJD3/KDM6B in Colorectal Cancer

  • Ryuma Tokunaga
  • Yasuo Sakamoto
  • Shigeki Nakagawa
  • Keisuke Miyake
  • Daisuke Izumi
  • Keisuke Kosumi
  • Katsunobu Taki
  • Takaaki Higashi
  • Yu Imamura
  • Takatsugu Ishimoto
  • Masaaki Iwatsuki
  • Yoshifumi Baba
  • Yuji Miyamoto
  • Naoya Yoshida
  • Eiji Oki
  • Masayuki Watanabe
  • Hideo BabaEmail author
Translational Research and Biomarkers



Jumonji-domain containing 3 (JMJD3) affects transcriptional regulation by demethylating lysine 27 residue of histone 3. We investigated its function and prognostic significance in colorectal cancer (CRC).


The influence of JMJD3 on cell proliferation was assessed using quantitative RT-PCR and western blot on the downstream target gene of JMJD3, in knock-down (KD) experiments and clinical samples from 151 CRC patients.


Cells with KD JMJD3 significantly increased proliferation through cell cycle progression and apoptosis suppression. Expression of P15INK4B was remarkably decreased in KD JMJD3 cells; and JMJD3 expression strongly correlated with p15INK4B expression in clinical CRC samples (P < 0.001, r = 0.566). Low JMJD3 also was an independent predictor of poor prognosis (P = 0.042) in surgically resected CRC patients.


JMJD3 has prognostic significance in CRC and mediates p15INK4B expression. These results imply that elucidation of the JMJD3 role may lead to a new therapeutic approach for CRC patients.


Overall Survival Suppress Apoptosis Normal Colorectal Epithelial Tissue JMJD3 Expression p16INK4A mRNA 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors thank Naomi Yokoyama, Yoko Ogata, and Hiroko Taniguchi for their valuable technical assistance.


The authors have no conflict of interest to declare.

Supplementary material

10434_2015_4879_MOESM1_ESM.docx (17 kb)
Supplementary material 1 (DOCX 17 kb)
10434_2015_4879_MOESM2_ESM.docx (23 kb)
Supplementary material 2 (DOCX 23 kb)
10434_2015_4879_MOESM3_ESM.docx (83 kb)
Supplementary material 3 (DOCX 83 kb)
10434_2015_4879_MOESM4_ESM.tiff (2 mb)
Supplementary material 4 (TIFF 2055 kb)
10434_2015_4879_MOESM5_ESM.tif (3.7 mb)
Supplementary material 5 (TIFF 3753 kb)
10434_2015_4879_MOESM6_ESM.tiff (2.8 mb)
Supplementary material 6 (TIFF 2826 kb)
10434_2015_4879_MOESM7_ESM.tiff (3.6 mb)
Supplementary material 7 (TIFF 3707 kb)


  1. 1.
    Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet. 2006;7:715-27.PubMedCrossRefGoogle Scholar
  2. 2.
    Agger K, Cloos PA, Christensen J, et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature. 2007;449:731-4.PubMedCrossRefGoogle Scholar
  3. 3.
    Hubner MR, Spector DL. Role of H3K27 demethylases Jmjd3 and UTX in transcriptional regulation. Cold Spring Harb Symp Quant Biol. 2010;75:43-9.PubMedCrossRefGoogle Scholar
  4. 4.
    Chen S, Ma J, Wu F, et al. The histone H3 Lys 27 demethylase JMJD3 regulates gene expression by impacting transcriptional elongation. Genes Dev. 2012;26:1364-75.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Yoo KH, Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci. 2012;8:59-65.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res. 2011;17:2613-8.PubMedCrossRefGoogle Scholar
  7. 7.
    Nakagawa S, Okabe H, Sakamoto Y, et al. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Ann Surg Oncol. 2013;20(Suppl 3):S667-75.PubMedCrossRefGoogle Scholar
  8. 8.
    Nakahara O, Takamori H, Iwatsuki M, et al. Carcinogenesis of intraductal papillary mucinous neoplasm of the pancreas: loss of microRNA-101 promotes overexpression of histone methyltransferase EZH2. Ann Surg Oncol. 2012;19(Suppl 3):S565-71.PubMedCrossRefGoogle Scholar
  9. 9.
    Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624-9.PubMedCrossRefGoogle Scholar
  10. 10.
    Nakagawa S, Sakamoto Y, Okabe H, et al. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells. Oncol Rep. 2014;31:983-8.PubMedGoogle Scholar
  11. 11.
    Popov N, Gil J. Epigenetic regulation of the INK4b-ARF-INK4a locus: in sickness and in health. Epigenetics. 2010;5:685-90.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Agger K, Cloos PA, Rudkjaer L, et al. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev. 2009;23:1171-6.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Satoh T, Takeuchi O, Vandenbon A, et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol. 2010;11:936-44.PubMedCrossRefGoogle Scholar
  14. 14.
    Xiang Y, Zhu Z, Han G, Lin H, Xu L, Chen CD. JMJD3 is a histone H3K27 demethylase. Cell Res. 2007;17:850-7.PubMedCrossRefGoogle Scholar
  15. 15.
    Shen Y, Guo X, Wang Y, et al. Expression and significance of histone H3K27 demethylases in renal cell carcinoma. BMC Cancer. 2012;12:470.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Pereira F, Barbachano A, Silva J, et al. KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells. Hum Mol Genet. 2011;20:4655-65.PubMedCrossRefGoogle Scholar
  17. 17.
    Pereira F, Barbachano A, Singh PK, Campbell MJ, Munoz A, Larriba MJ. Vitamin D has wide regulatory effects on histone demethylase genes. Cell Cycle. 2012;11:1081-9.PubMedCrossRefGoogle Scholar
  18. 18.
    Martinelli P, Bonetti P, Sironi C, et al. The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. Blood. 2011;117:6617-26.PubMedCrossRefGoogle Scholar
  19. 19.
    Fluge O, Gravdal K, Carlsen E, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer. 2009;101:1282-9.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Ishikawa S, Hayashi H, Kinoshita K, et al. Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer. Int J Cancer. 2014;135:2528-36.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Tae S, Karkhanis V, Velasco K, et al. Bromodomain protein 7 interacts with PRMT5 and PRC2, and is involved in transcriptional repression of their target genes. Nucleic Acids Res. 2011;39:5424-38.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Svotelis A, Bianco S, Madore J, et al. H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ERalpha ligand dependency. EMBO J. 2011;30:3947-61.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Ene CI, Edwards L, Riddick G, et al. Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by regulating p53 protein nuclear stabilization. PLoS One. 2012;7:e51407.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Kamikawa Y, Donohoe M. The localization of histone H3K27me3 demethylase Jmjd3 is dynamically regulated. Epigenetics. 2014;9:834-41.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Gomez-Sanchez JA, Gomis-Coloma C, Morenilla-Palao C, et al. Epigenetic induction of the Ink4a/Arf locus prevents Schwann cell overproliferation during nerve regeneration and after tumorigenic challenge. Brain. 2013;136:2262-78.PubMedCrossRefGoogle Scholar
  26. 26.
    Li J, Poi MJ, Tsai MD. Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry. 2011;50:5566-82.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Lang JC, Borchers J, Danahey D, et al. Mutational status of overexpressed p16 in head and neck cancer: evidence for germline mutation of p16/p14ARF. Int J Oncol. 2002;21:401-8.PubMedGoogle Scholar
  28. 28.
    Krimpenfort P, Ijpenberg A, Song JY, et al. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature. 2007;448:943-6.PubMedCrossRefGoogle Scholar
  29. 29.
    Yamamoto K, Tateishi K, Kudo Y, et al. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPalpha. Carcinogenesis. 2014;35:2404-14.PubMedCrossRefGoogle Scholar
  30. 30.
    Sugihara H, Ishimoto T, Watanabe M, et al. Identification of miR-30e* regulation of Bmi1 expression mediated by tumor-associated macrophages in gastrointestinal cancer. PLoS One. 2013;8:e81839.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Riquelme E, Suraokar M, Behrens C, et al. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res. 2014;20:3849-61.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:4706-13.PubMedCrossRefGoogle Scholar
  33. 33.
    Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-9.PubMedCrossRefGoogle Scholar
  34. 34.
    Salminen A, Kaarniranta K, Hiltunen M, Kauppinen A. Histone demethylase Jumonji D3 (JMJD3/KDM6B) at the nexus of epigenetic regulation of inflammation and the aging process. J Mol Med (Berl). 2014;92:1035-43.PubMedCrossRefGoogle Scholar
  35. 35.
    Zhao W, Li Q, Ayers S, et al. Jmjd3 inhibits reprogramming by upregulating expression of INK4a/Arf and targeting PHF20 for ubiquitination. Cell. 2013;152:1037–50.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2015

Authors and Affiliations

  • Ryuma Tokunaga
    • 1
  • Yasuo Sakamoto
    • 1
  • Shigeki Nakagawa
    • 1
  • Keisuke Miyake
    • 1
  • Daisuke Izumi
    • 1
  • Keisuke Kosumi
    • 1
  • Katsunobu Taki
    • 1
  • Takaaki Higashi
    • 1
  • Yu Imamura
    • 1
  • Takatsugu Ishimoto
    • 1
  • Masaaki Iwatsuki
    • 1
  • Yoshifumi Baba
    • 1
  • Yuji Miyamoto
    • 1
  • Naoya Yoshida
    • 1
  • Eiji Oki
    • 2
  • Masayuki Watanabe
    • 3
  • Hideo Baba
    • 1
    Email author
  1. 1.Department of Gastroenterological Surgery, Graduate School of Medical SciencesKumamoto UniversityKumamotoJapan
  2. 2.Department of Surgery and Sciences, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  3. 3.Department of Gastroenterological SurgeryJapanese Foundation for Cancer ResearchTokyoJapan

Personalised recommendations